multiple myeloma clinical trials results

Elotuzumab Lenalidomide Dexamethasone versus Lenalidomide + Dexamethasone
ELOQUENT - 1, 0
NCT01335399

versus
Newly Diagnosed, Previously Untreated Multiple Myelomaopen label
USA
carfilzomib versus placebo (on top lenalidomide and dexamethasone)
ASPIRE, 2015
NCT01080391
carfilzomib with lenalidomide and dexamethasone
versus
lenalidomide and dexamethasone alone
patients with relapsed multiple myelomaopen-label
CTDa versus MP
MRC Myeloma IX,
ISRCTN68454111
CTDa
versus
MP
elotuzumab versus placebo (on top lenalidomide and dexamethasone)
ELOQUENT 2, 2015
NCT01239797
elotuzumab plus lenalidomide and dexamethasone
versus
lenalidomide and dexamethasone alone
patients with Relapsed or Refractory Multiple Myelomaopen-label
Elotuzumab Lenalidomide Dexamethasone versus Lenalidomide + Dexamethasone
ELOQUENT - 2, 0
NCT01239797
Lenalidomide + Dexamethasone +Elotuzumab
versus
Lenalidomide + Dexamethasone
patients with Relapsed or Refractory Multiple Myeloma
MPR + CPR versus Rd
NR 2013,
MPR + CPR
versus
Rd
MPR+R versus MP
MM-015,
NCT00405756
MPR+R
versus
MP
MPR+R versus MPT+T
EIA06 (NCT00602641), 0
NCT00602641
MPR+R
versus
MPT+T
MPT versus MP
IFM 01/01,
MPT
versus
MP
IFM 99/06,
NCT00367185
MPT
versus
MP
NCT01274403,
NCT01274403
MPT
versus
MP
MPT+T versus MP
GIMEMA,
NCT00232934
MPT+T
versus
MP
HOVON 49,
ISRCTN90692740
MPT+T
versus
MP
NMSG,
MPT+T
versus
MP
TMSG,
NCT00934154
MPT+T
versus
MP
PCAB+IFN-2a versus PCAB
NR 1997,
PCAB+IFN-2a
versus
PCAB
Rd ou Rd18 versus MPT
FIRST ,
NCT00689936
Rd ou Rd18
versus
MPT
VMP versus MP
VISTA,
NCT00111319
VMP
versus
MP
VMP + siltuximab versus VMP
NCT00911859,
NCT00911859
VMP + siltuximab
versus
VMP
VMPT+VT versus VMP
NR 2010,
VMPT+VT
versus
VMP